EGFR-targeted immunoliposomes carrying cabazitaxel displayed reduced particle size, high encapsulation efficiency, and superior cytotoxicity and antitumor effects, significantly extending survival with reduced toxicity in EGFR-overexpressing PCa models [207]. The gene discussed is EGFR; the disease is posterior cortical atrophy.